<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219856</url>
  </required_header>
  <id_info>
    <org_study_id>AFSSAPS 040366</org_study_id>
    <secondary_id>PHRC/03-02</secondary_id>
    <secondary_id>CIC0203/026</secondary_id>
    <nct_id>NCT00219856</nct_id>
  </id_info>
  <brief_title>Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy</brief_title>
  <official_title>Prospective, Randomized, Simple Blind Study Comparing the Effects of an Anaesthesia With Propofol to an Anaesthesia With Desflurane on Oxydative Stress and Liver Function Recovery After Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol is an anaesthetic agent that showed in vitro and in vivo anti oxidant properties. No&#xD;
      data are available concerning the potential benefit of a total anaesthesia with propofol in&#xD;
      partial hepatic surgery. Patients who undergo partial hepatic resection have frequent liver&#xD;
      insufficiency that could be related in part to the oxidative stress induced by clamping the&#xD;
      hepatic vessels during the surgical intervention. Our hypothesis is that propofol, by&#xD;
      increasing liver resistance to this ischemia-reperfusion phenomenon, could improve the&#xD;
      remaining liver function recovery, and therefore could reduce post surgical morbidity.&#xD;
&#xD;
      The aim of the study is to evaluate the anti oxidant effects of propofol compared to another&#xD;
      widely used anaesthetic agent, inhaled desflurane, during and after partial hepatic resection&#xD;
      with hepatic vessels clamping. The primary endpoint will be the level of malondialdehyde (a&#xD;
      plasmatic marker of oxidative stress), 30 minutes after the end of hepatic clamping.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Propofol is an anaesthetic agent that showed in vitro and in vivo anti oxidant properties. No&#xD;
      data are available concerning the potential benefit of a total anaesthesia with propofol in&#xD;
      partial hepatic surgery. Patients who undergo partial hepatic resection have frequent liver&#xD;
      insufficiency that could be related in part to the oxidative stress induced by clamping the&#xD;
      hepatic hilum during the surgical intervention. Our hypothesis is that propofol, by&#xD;
      increasing liver resistance to ischemic-reperfusion injury, could improve the remaining liver&#xD;
      function recovery, and therefore could reduce post surgical morbidity.&#xD;
&#xD;
      The aim of the study is to evaluate the anti oxidant effects of propofol compared to another&#xD;
      widely used anaesthetic agent, inhaled desflurane, during and after partial hepatic resection&#xD;
      with hepatic hilum clamping.&#xD;
&#xD;
      The primary endpoint will be the level of malondialdehyde (a plasmatic marker of oxidative&#xD;
      stress), 30 minutes after the end of hepatic clamping.&#xD;
&#xD;
      The evolution over time of other markers of oxidative stress will be studied (glutathione,&#xD;
      myeloperoxidase, nitric oxide), as well as functional and biological markers of liver&#xD;
      regeneration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma MDA levels</measure>
    <time_frame>30 minutes after the end of hepatic clamping</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics of post surgical biological hepatic function recovery</measure>
    <time_frame>Days 1, 2, 5, 10</time_frame>
    <description>Gamma gluatamyltransferase&#xD;
ASAT&#xD;
ALAT&#xD;
Factor V&#xD;
AlfagluthationeS-transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of post surgical hepatic function recovery</measure>
    <time_frame>Day 2</time_frame>
    <description>Monoethylglycinexylidide (MEGX) test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other biological markers of oxidative stress</measure>
    <time_frame>Days 1 and 2</time_frame>
    <description>Glutathione&#xD;
Myeloperoxidase&#xD;
Nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics during and after surgery</measure>
    <time_frame>Days 1 and 2</time_frame>
    <description>Mean arterial pressure&#xD;
Heart rate&#xD;
Diuresis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery related complications</measure>
    <time_frame>10 days</time_frame>
    <description>Liver insufficiency&#xD;
Hepato renal syndrome&#xD;
Local infections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hepatectomy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anesthesic induction and maintenance with intravenous propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml&#xD;
Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penthotal</intervention_name>
    <description>Intravenous penthotal at the dose of 3 to 5 mg/kg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18&#xD;
&#xD;
          -  Need for partial hepatic resection requiring heptic clamping&#xD;
&#xD;
          -  Resection of 4 liver segments or less&#xD;
&#xD;
          -  In case of cirrhosis, child A&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Hemochromatosis&#xD;
&#xD;
          -  chemotherapy in the previous week before inclusion&#xD;
&#xD;
          -  Thrombosis of the portal vein or the hepatic artery&#xD;
&#xD;
          -  Absence of contraception among fertil woman&#xD;
&#xD;
          -  Concomitant treatment that could have potential interaction with propofol&#xD;
&#xD;
          -  Concomitant treatment known to have antioxidant properties&#xD;
&#xD;
          -  Inclusion in another study protocol using a medication incompatible with the present&#xD;
             study&#xD;
&#xD;
          -  Patient in which the follow up seems impossible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Aguillon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yannick Malledant, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Laviolle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgical Intensive Care Unit - Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Direction of Clinical Research</name_title>
    <organization>Rennes University Hospital</organization>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>Oxidative stress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

